The Asia Pacific In Situ Hybridization Market would witness market growth of 7.8% CAGR during the forecast period (2022-2028).
Technology developments in the IVD sector are the main drivers of the in situ hybridization (ISH) market. One of the primary technological developments that have led to prosperous business potential is the development of 3D FISH technology. It makes it easier to see and analyze target cells from a 3D perspective, leading to the best study results.
Therefore, numerous strategic efforts are being undertaken by different businesses to combine their resources for technological growth. Additionally, research based on the use of FISH technology for identifying chromosome modifications in pathology archives concluded that FISH images are among the best alternatives for validating SNP microarray analysis because they are reliable in identifying abnormalities like uniparental disomy.
Additionally, it is a completely automated approach for detecting prenatal cancer that reduces the time needed for diagnostic and research applications by providing quicker and more reliable findings. Major In Situ Hybridization (ISH) market companies and independent research communities are expected to invest in various research projects due to the aforementioned considerations.
In comparison to other places, the development of illnesses like chronic lymphocytic leukaemia (CLL) is quick in this one. Particularly, Southeast Asian countries are seeing a sharp rise in the frequency of lymphoma in the area. Additionally, Australia and its adjacent nations have the highest age-standardized rates of multiple myeloma (MM) in the whole globe. Blood cancer affects 60,000 Australians, on average. Hematologic malignancies are becoming more common in other countries as well. For instance, leukaemia is now China's tenth most prevalent cancer-related cause of death. The ISH market is expected to have considerable growth in the APAC region due to the growing incidence of cancer.
The China market dominated the Asia Pacific In Situ Hybridization Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $121.7 million by 2028.The Japan market is estimated to grow a CAGR of 7.2% during (2022 - 2028). Additionally, The India market would experience a CAGR of 8.5% during (2022 - 2028).
Based on Technology, the market is segmented into Fluorescent In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH). Based on End Use, the market is segmented into Research & Diagnostic Laboratories, Academic Institutes, CROs and Others. Based on Application, the market is segmented into Cancer, Cytogenetics, Developmental Biology, Infectious Diseases and Others. Based on Product, the market is segmented into Instruments, Kits & Probes, Software and Services. Based on Probe, the market is segmented into DNA and RNA. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Abbott Laboratories, PerkinElmer, Inc., Agilent Technologies, Inc., Merck Group, Bio-Rad Laboratories, Inc., Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.), Danaher Corporation (Leica Biosystems), F. Hoffmann-La Roche Ltd., and Neogenomics, Inc.
Technology developments in the IVD sector are the main drivers of the in situ hybridization (ISH) market. One of the primary technological developments that have led to prosperous business potential is the development of 3D FISH technology. It makes it easier to see and analyze target cells from a 3D perspective, leading to the best study results.
Therefore, numerous strategic efforts are being undertaken by different businesses to combine their resources for technological growth. Additionally, research based on the use of FISH technology for identifying chromosome modifications in pathology archives concluded that FISH images are among the best alternatives for validating SNP microarray analysis because they are reliable in identifying abnormalities like uniparental disomy.
Additionally, it is a completely automated approach for detecting prenatal cancer that reduces the time needed for diagnostic and research applications by providing quicker and more reliable findings. Major In Situ Hybridization (ISH) market companies and independent research communities are expected to invest in various research projects due to the aforementioned considerations.
In comparison to other places, the development of illnesses like chronic lymphocytic leukaemia (CLL) is quick in this one. Particularly, Southeast Asian countries are seeing a sharp rise in the frequency of lymphoma in the area. Additionally, Australia and its adjacent nations have the highest age-standardized rates of multiple myeloma (MM) in the whole globe. Blood cancer affects 60,000 Australians, on average. Hematologic malignancies are becoming more common in other countries as well. For instance, leukaemia is now China's tenth most prevalent cancer-related cause of death. The ISH market is expected to have considerable growth in the APAC region due to the growing incidence of cancer.
The China market dominated the Asia Pacific In Situ Hybridization Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $121.7 million by 2028.The Japan market is estimated to grow a CAGR of 7.2% during (2022 - 2028). Additionally, The India market would experience a CAGR of 8.5% during (2022 - 2028).
Based on Technology, the market is segmented into Fluorescent In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH). Based on End Use, the market is segmented into Research & Diagnostic Laboratories, Academic Institutes, CROs and Others. Based on Application, the market is segmented into Cancer, Cytogenetics, Developmental Biology, Infectious Diseases and Others. Based on Product, the market is segmented into Instruments, Kits & Probes, Software and Services. Based on Probe, the market is segmented into DNA and RNA. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Abbott Laboratories, PerkinElmer, Inc., Agilent Technologies, Inc., Merck Group, Bio-Rad Laboratories, Inc., Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.), Danaher Corporation (Leica Biosystems), F. Hoffmann-La Roche Ltd., and Neogenomics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Technology
- Fluorescent In Situ Hybridization (FISH)
- Chromogenic In Situ Hybridization (CISH)
By End Use
- Research & Diagnostic Laboratories
- Academic Institutes
- CROs
- Others
By Application
- Cancer
- Cytogenetics
- Developmental Biology
- Infectious Diseases
- Others
By Product
- Instruments
- Kits & Probes
- Software
- Services
By Probe
- DNA
- RNA
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc
- Abbott Laboratories
- PerkinElmer, Inc
- Agilent Technologies, Inc
- Merck Group
- Bio-Rad Laboratories, Inc
- Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
- Danaher Corporation (Leica Biosystems)
- F. Hoffmann-La Roche Ltd
- Neogenomics, Inc
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific In Situ Hybridization Market, by Technology
1.4.2 Asia Pacific In Situ Hybridization Market, by End Use
1.4.3 Asia Pacific In Situ Hybridization Market, by Application
1.4.4 Asia Pacific In Situ Hybridization Market, by Product
1.4.5 Asia Pacific In Situ Hybridization Market, by Probe
1.4.6 Asia Pacific In Situ Hybridization Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific In Situ Hybridization Market by Technology
3.1 Asia Pacific Fluorescent In Situ Hybridization (FISH) Market by Country
3.2 Asia Pacific Chromogenic In Situ Hybridization (CISH) Market by Country
Chapter 4. Asia Pacific In Situ Hybridization Market by End-use
4.1 Asia Pacific Research & Diagnostic Laboratories Market by Country
4.2 Asia Pacific Academic Institutes Market by Country
4.3 Asia Pacific CROs Market by Country
4.4 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific In Situ Hybridization Market by Application
5.1 Asia Pacific Cancer Market by Country
5.2 Asia Pacific Cytogenetics Market by Country
5.3 Asia Pacific Developmental Biology Market by Country
5.4 Asia Pacific Infectious Diseases Market by Country
5.5 Asia Pacific Others Market by Country
Chapter 6. Asia Pacific In Situ Hybridization Market by Product
6.1 Asia Pacific Instruments Market by Country
6.2 Asia Pacific Kits & Probes Market by Country
6.3 Asia Pacific Software Market by Country
6.4 Asia Pacific Services Market by Country
Chapter 7. Asia Pacific In Situ Hybridization Market by Probe
7.1 Asia Pacific DNA Market by Country
7.2 Asia Pacific RNA Market by Country
Chapter 8. Asia Pacific In Situ Hybridization Market by Country
8.1 China In Situ Hybridization Market
8.1.1 China In Situ Hybridization Market by Technology
8.1.2 China In Situ Hybridization Market by End-use
8.1.3 China In Situ Hybridization Market by Application
8.1.4 China In Situ Hybridization Market by Product
8.1.5 China In Situ Hybridization Market by Probe
8.2 Japan In Situ Hybridization Market
8.2.1 Japan In Situ Hybridization Market by Technology
8.2.2 Japan In Situ Hybridization Market by End-use
8.2.3 Japan In Situ Hybridization Market by Application
8.2.4 Japan In Situ Hybridization Market by Product
8.2.5 Japan In Situ Hybridization Market by Probe
8.3 India In Situ Hybridization Market
8.3.1 India In Situ Hybridization Market by Technology
8.3.2 India In Situ Hybridization Market by End-use
8.3.3 India In Situ Hybridization Market by Application
8.3.4 India In Situ Hybridization Market by Product
8.3.5 India In Situ Hybridization Market by Probe
8.4 South Korea In Situ Hybridization Market
8.4.1 South Korea In Situ Hybridization Market by Technology
8.4.2 South Korea In Situ Hybridization Market by End-use
8.4.3 South Korea In Situ Hybridization Market by Application
8.4.4 South Korea In Situ Hybridization Market by Product
8.4.5 South Korea In Situ Hybridization Market by Probe
8.5 Singapore In Situ Hybridization Market
8.5.1 Singapore In Situ Hybridization Market by Technology
8.5.2 Singapore In Situ Hybridization Market by End-use
8.5.3 Singapore In Situ Hybridization Market by Application
8.5.4 Singapore In Situ Hybridization Market by Product
8.5.5 Singapore In Situ Hybridization Market by Probe
8.6 Malaysia In Situ Hybridization Market
8.6.1 Malaysia In Situ Hybridization Market by Technology
8.6.2 Malaysia In Situ Hybridization Market by End-use
8.6.3 Malaysia In Situ Hybridization Market by Application
8.6.4 Malaysia In Situ Hybridization Market by Product
8.6.5 Malaysia In Situ Hybridization Market by Probe
8.7 Rest of Asia Pacific In Situ Hybridization Market
8.7.1 Rest of Asia Pacific In Situ Hybridization Market by Technology
8.7.2 Rest of Asia Pacific In Situ Hybridization Market by End-use
8.7.3 Rest of Asia Pacific In Situ Hybridization Market by Application
8.7.4 Rest of Asia Pacific In Situ Hybridization Market by Product
8.7.5 Rest of Asia Pacific In Situ Hybridization Market by Probe
Chapter 9. Company Profiles
9.1 Thermo Fisher Scientific, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.2 Abbott Laboratories
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 SWOT Analysis
9.3 PerkinElmer, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.4 Agilent Technologies, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.5 Merck Group
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.6 Bio-Rad laboratories, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expenses
9.7 Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.8 Danaher Corporation (Leica Biosystems)
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.9 F. Hoffmann-La Roche Ltd.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expense
9.10. Neogenomics, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental Analysis
9.10.4 Research & Development Expenses
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Abbott Laboratories
- PerkinElmer, Inc.
- Agilent Technologies, Inc.
- Merck Group
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
- Danaher Corporation (Leica Biosystems)
- F. Hoffmann-La Roche Ltd.
- Neogenomics, Inc.
Methodology
LOADING...
